MarketPeel
Insider Trading Intelligence
Pricing
…
RL

Richard E. Lowenthal

SPRY
PRESIDENT AND CEO · ARS PHARMACEUTICALS, INC. · CIK 0001378550
FILING MIX · LIFETIME23%/77%
BUYS
23
SELLS
79
TOTAL VALUE
$22.99M
COMPANIES
1
ACTIVE SINCE
Nov 2022
HOLDINGS NOW
240,000
AVG SELL PX
$11.49
TRADE KIND
SHOWING 102 / 102
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
52 backtested trades · 8 horizons · 29 pending
Forward-return performance of every backtestable P/S trade by Richard E. Lowenthal, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d52+65.38%-1.00%+0.80%-1.80%-2.78%-1.48
14d52+71.15%-4.54%+0.67%-5.20%-4.92%-3.84
30d52+61.54%+1.88%+2.35%-0.47%-3.25%-0.24
60d52+40.38%+3.87%+3.31%+0.56%+2.24%0.22
90d52+48.08%+5.92%+3.96%+1.96%-1.95%0.61
180d52+42.31%+24.96%+8.04%+16.92%+20.31%3.39
1y52(1 pending)+41.18%+14.97%+14.88%+0.09%+1.03%0.02
2y52(28 pending)+50.00%-1.20%+38.96%-40.15%-39.36%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
SPRY · 240,000 shares · as of Jan 2, 2026
01,294,2062,588,4113,882,6175,176,8222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 23 buys / 79 sellsCOVERAGE · 14 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
875,000——875,000Jan 2, 2026Jan 5, 2026 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
240,000——240,000Jan 2, 2026Jan 5, 2026 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
50,000$14.49$724.3K1,196,494Aug 21, 2025Aug 22, 2025 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
261,900——261,900Jan 2, 2025Jan 3, 2025 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
767,600——767,600Jan 2, 2025Jan 3, 2025 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
50,000$11.67$583.6K1,297,447Dec 17, 2024Dec 19, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
50,000$11.67$583.5K1,098,499Dec 17, 2024Dec 19, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
50,000$13.17$658.3K1,246,494Dec 10, 2024Dec 11, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
50,000$13.16$658.2K1,148,499Dec 10, 2024Dec 11, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
PRESIDENT AND CEO
11,876$8.42$100.0K4,327,189Dec 6, 2024Dec 9, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
PRESIDENT AND CEO
13,789$1.44$19.9K3,421,636Dec 6, 2024Dec 9, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
PRESIDENT AND CEO
11,876$8.42$100.0K3,433,512Dec 6, 2024Dec 9, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
PRESIDENT AND CEO
11,876——1,088,124Dec 6, 2024Dec 9, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
PRESIDENT AND CEO
13,789——20,684Dec 6, 2024Dec 9, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
PRESIDENT AND CEO
11,876——338,124Dec 6, 2024Dec 9, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
50,000$13.95$697.5K1,347,447Nov 19, 2024Nov 21, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
50,000$13.95$697.5K1,198,499Nov 19, 2024Nov 21, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
45,124$16.76$756.3K1,253,375Nov 12, 2024Nov 14, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
45,045$16.76$754.9K1,301,449Nov 12, 2024Nov 14, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
4,955$17.64$87.4K1,296,494Nov 12, 2024Nov 14, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
4,876$17.64$86.0K1,248,499Nov 12, 2024Nov 14, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
1,450$15.25$22.1K1,397,447Oct 15, 2024Oct 17, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
50,000$14.88$743.8K1,298,499Oct 15, 2024Oct 17, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
48,550$14.86$721.7K1,398,897Oct 15, 2024Oct 17, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
50,000$12.93$646.5K1,447,447Sep 17, 2024Sep 19, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
50,000$12.93$646.7K1,398,499Sep 17, 2024Sep 19, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
50,000$11.50$574.9K1,396,494Sep 10, 2024Sep 12, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
50,000$11.50$574.9K1,448,499Sep 10, 2024Sep 12, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
11,756$15.61$183.5K1,499,747Aug 20, 2024Aug 21, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
36,216$14.76$534.5K1,512,283Aug 20, 2024Aug 21, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
2,261$16.25$36.7K1,498,499Aug 20, 2024Aug 21, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
35,944$14.76$530.4K1,511,503Aug 20, 2024Aug 21, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
2,300$16.26$37.4K1,497,447Aug 20, 2024Aug 21, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
11,523$15.62$180.0K1,500,760Aug 20, 2024Aug 21, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
14,599$11.78$171.9K1,481,895Aug 13, 2024Aug 15, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
14,637$11.77$172.3K1,583,862Aug 13, 2024Aug 15, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
35,363$12.77$451.4K1,548,499Aug 13, 2024Aug 15, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
35,401$12.76$451.9K1,446,494Aug 13, 2024Aug 15, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
50,000$11.40$570.1K1,547,447Jul 16, 2024Jul 18, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
50,000$11.40$570.2K1,598,499Jul 16, 2024Jul 18, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
50,000$9.62$480.9K1,496,494Jul 9, 2024Jul 11, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
50,000$9.62$480.8K1,648,499Jul 9, 2024Jul 11, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
48,028$9.14$439.2K1,698,499Jun 12, 2024Jun 13, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
47,834$9.15$437.5K1,546,494Jun 12, 2024Jun 13, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
2,166$9.00$19.5K1,594,328Jun 11, 2024Jun 13, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
1,972$9.00$17.8K1,746,527Jun 11, 2024Jun 13, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
44,746$9.06$405.3K1,597,447May 16, 2024May 16, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
44,350$9.06$401.7K1,748,499May 16, 2024May 16, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
2,381$9.05$21.6K1,642,193May 15, 2024May 16, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
2,766$9.04$25.0K1,792,849May 15, 2024May 16, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
2,884$9.01$26.0K1,795,615May 14, 2024May 16, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
2,873$9.01$25.9K1,644,574May 14, 2024May 16, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
50,000$9.34$467.2K1,798,499May 7, 2024May 9, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
50,000$9.34$467.1K1,596,494May 7, 2024May 9, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
PRESIDENT AND CEO
48,260$1.44$69.5K3,407,847Apr 23, 2024Apr 24, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
PRESIDENT AND CEO
82,733$0.84$69.5K3,359,587Apr 23, 2024Apr 24, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
PRESIDENT AND CEO
82,733——0Apr 23, 2024Apr 24, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
PRESIDENT AND CEO
48,260——34,473Apr 23, 2024Apr 24, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
PRESIDENT AND CEO
119,047——117,333Apr 19, 2024Apr 22, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
PRESIDENT AND CEO
69,444——166,936Apr 19, 2024Apr 22, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
PRESIDENT AND CEO
119,047$0.84$100.0K4,245,869Apr 19, 2024Apr 22, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
PRESIDENT AND CEO
69,444$1.44$100.0K4,315,313Apr 19, 2024Apr 22, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
50,000$9.28$464.0K1,647,447Apr 16, 2024Apr 17, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
50,000$9.28$464.0K1,848,499Apr 16, 2024Apr 17, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
50,000$9.28$463.9K1,898,499Apr 9, 2024Apr 10, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
50,000$9.28$463.9K1,646,494Apr 9, 2024Apr 10, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
47,635$9.12$434.6K1,697,447Mar 25, 2024Mar 26, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
47,632$9.12$434.6K1,948,499Mar 25, 2024Mar 26, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
1,326$9.01$12.0K1,996,131Mar 22, 2024Mar 26, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
1,017$9.03$9.2K1,745,082Mar 22, 2024Mar 26, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
100$9.00$9001,997,457Mar 21, 2024Mar 21, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
372$9.00$3.3K1,746,099Mar 21, 2024Mar 21, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
976$9.03$8.8K1,746,471Mar 19, 2024Mar 21, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
942$9.04$8.5K1,997,557Mar 19, 2024Mar 21, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
48,295$9.14$441.5K1,696,494Mar 15, 2024Mar 15, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
48,461$9.14$443.0K1,998,499Mar 15, 2024Mar 15, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
239$9.00$2.2K2,046,960Mar 14, 2024Mar 15, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
205$9.00$1.8K1,744,789Mar 14, 2024Mar 15, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
1,300$9.00$11.7K2,047,199Mar 13, 2024Mar 15, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
1,500$9.00$13.5K1,744,994Mar 13, 2024Mar 15, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
800$9.02$7.2K1,746,494Feb 29, 2024Mar 1, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
1,000$9.02$9.0K1,747,447Feb 29, 2024Mar 1, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
1,982$9.01$17.9K2,048,499Feb 29, 2024Mar 1, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
24,303$9.02$219.2K1,748,447Feb 28, 2024Feb 28, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
49,019$9.02$442.2K2,050,481Feb 28, 2024Feb 28, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
25,456$9.02$229.6K1,747,294Feb 28, 2024Feb 28, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
500$9.01$4.5K2,099,500Feb 26, 2024Feb 28, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
100$9.01$9011,772,750Feb 26, 2024Feb 28, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
880,000——880,000Jan 2, 2024Jan 4, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
300,000——300,000Jan 2, 2024Jan 4, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALEGRANT
Gift
1,050,000——4,126,822May 17, 2023Jan 4, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Gift
1,050,000——1,050,000May 17, 2023Jan 4, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALEGRANT
Gift
1,050,000——3,276,854May 17, 2023Jan 4, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Gift
1,050,000——2,100,000May 17, 2023Jan 4, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
350,000——350,000Jan 3, 2023Jan 5, 2023 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
1,100,000——1,100,000Jan 3, 2023Jan 5, 2023 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
236,380——236,380Nov 8, 2022Nov 10, 2022 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
82,733——82,733Nov 8, 2022Nov 10, 2022 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
1,772,850——1,772,850Nov 8, 2022Nov 10, 2022 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
4,326,854——4,326,854Nov 8, 2022Nov 10, 2022 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
82,733——82,733Nov 8, 2022Nov 10, 2022 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
5,176,822——5,176,822Nov 8, 2022Nov 10, 2022 ↗View →
Other insiders · SPRY
Loading peer insiders…
About this filer
CIK 0001378550
ROLE
PRESIDENT AND CEO
PRIMARY
SPRY
COMPANIES
1
ACTIVE SINCE
Nov 2022
MARKETPEEL · /INSIDER/0001378550DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback